Radioactive seeds aim to boost tumor control in patients with 6-10 metastases

NCT ID NCT07333664

Not yet recruiting Disease control Sponsor: Li Min Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding image-guided radioactive seed implants to standard cancer therapy can improve disease control in patients with 6 to 10 metastatic tumors. About 120 adults with solid tumors that have spread will be randomly assigned to receive either standard therapy alone or standard therapy plus the seed implants. The study will measure progression-free survival, overall survival, safety, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodine-125 radioactive seeds
What this could lead to: If it works, this could offer a new way to control multiple metastatic tumors by combining standard drugs with targeted radiation implants.
What could go wrong: This is an early phase 2 study with only 120 participants, so results may not apply to everyone. The procedure carries risks like radiation exposure or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMORS

Contacts and locations

Locations

The 960th Hospital of People's Liberation Army (PLA)

Jinan, Shandong, 250031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.